Actuate Therapeutics, Inc. (ACTU)
NASDAQ: ACTU · Real-Time Price · USD
2.080
+0.260 (14.29%)
At close: Apr 14, 2026, 4:00 PM EDT
2.080
0.00 (0.00%)
Pre-market: Apr 15, 2026, 6:25 AM EDT
Actuate Therapeutics Employees
Actuate Therapeutics had 12 employees as of December 31, 2025. The number of employees increased by 2 or 20.00% compared to the previous year.
Employees
12
Change (1Y)
2
Growth (1Y)
20.00%
Revenue / Employee
n/a
Profits / Employee
-$1,852,321
Market Cap
49.32M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 12 | 2 | 20.00% |
| Dec 31, 2024 | 10 | 5 | 100.00% |
| Sep 30, 2024 | 11 | 6 | 120.00% |
| Jun 30, 2024 | 11 | - | - |
| Mar 31, 2024 | 10 | - | - |
| Dec 31, 2023 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| NextCure | 40 |
| Werewolf Therapeutics | 39 |
| Veru Inc. | 20 |
| Atossa Therapeutics | 16 |
| Sensei Biotherapeutics | 15 |
| Hyperion DeFi | 14 |
| Atara Biotherapeutics | 14 |
| Rein Therapeutics | 10 |
ACTU News
- 23 hours ago - Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma - GlobeNewsWire
- 22 days ago - Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers - Accesswire
- 5 weeks ago - Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors - GlobeNewsWire
- 7 weeks ago - Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 3 months ago - Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026 - GlobeNewsWire
- 3 months ago - Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers - GlobeNewsWire
- 4 months ago - Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026 - GlobeNewsWire
- 7 months ago - Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months - GlobeNewsWire